Skip to main content
Figure 7 | Breast Cancer Research

Figure 7

From: Interpreting breast international group (BIG) 1-98: a randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer

Figure 7

Forest plot showing the relative risk of an adverse event. Grades 1 to 5 (a) and grades 3 to 5 (b) among the 4,895 patients who were assigned tamoxifen or letrozole monotherapy and who received some trial treatment. All patients had completed treatment (median follow-up of 76 months). AE, adverse event; CI, confidence interval; CVA/TIA, cerebral vascular accident/transient ischemic attack; MedDRA, Medical Dictionary for Regulatory Activities.

Back to article page